Albertsons Reaches $774M Opioid Settlement Amid Mixed Q4 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ACI?
Source: seekingalpha
- Settlement Agreement: Albertsons has reached a $774 million opioid settlement with state, local, and tribal governments, which, while not admitting any wrongdoing, significantly aids in resolving most related litigation, thereby reducing future legal risks.
- Mixed Financial Results: Despite a 7.7% year-over-year sales increase to $20.25 billion, driven by a 16% rise in digital sales and a 0.7% increase in pharmacy transactions, the results fell short of expectations by $200 million, putting the company under greater market pressure.
- Slight Profit Growth: The company reported an adjusted profit of $0.48 per share, up 2 cents from last year and beating expectations by 4 cents, indicating resilience in profitability amidst adverse conditions, although it does not mask the overall weakness in financial performance.
- Cautious Future Outlook: Albertsons anticipates flat to 1% growth in identical sales for FY26, with full-year profit projections between $2.22 and $2.32 per share, closely aligning with consensus estimates, yet reflecting a cautious stance on future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACI
Wall Street analysts forecast ACI stock price to rise
16 Analyst Rating
10 Buy
5 Hold
1 Sell
Moderate Buy
Current: 16.600
Low
17.00
Averages
22.27
High
29.00
Current: 16.600
Low
17.00
Averages
22.27
High
29.00
About ACI
Albertsons Companies, Inc. is a food and drug retailer in the United States. The Company is engaged in the operation of food and drug retail stores that offer grocery products, general merchandise, health and beauty care products, pharmacy, fuel and other items and services in its stores or through digital channels. It operates approximately 2,257 retail stores with 1,720 in-store pharmacies, 405 associated fuel centers, 22 dedicated distribution centers and 19 manufacturing facilities. The Company operates stores across 35 states and the District of Columbia under 22 banners, including Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, ACME, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen, Carrs, Kings Food Markets and Balducci's Food Lovers Market. Its own brands include Signature SELECT, Open Nature, Lucerne, Waterfront BISTRO, Signature Reserve and Value Corner, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Albertsons Companies Q4 Fiscal 2025 Earnings Call Insights
- Sales Growth: Albertsons reported a 0.7% increase in identical sales for Q4 fiscal 2025, despite facing headwinds in its pharmacy business, indicating resilience in a competitive market.
- Profitability Metrics: The adjusted EBITDA reached $903 million, exceeding expectations, reflecting positive outcomes in cost control and operational efficiency, which helps bolster investor confidence.
- Shareholder Return Strategy: The company returned over $1.8 billion to shareholders in fiscal 2025, including $322 million in dividends and nearly $1.5 billion in share repurchases, demonstrating a strong commitment to capital management and shareholder value.
- Future Outlook: Management guided identical sales growth for fiscal 2026 to be between 0% and 2.5%, facing ongoing pharmacy sales pressures, but aims for a transition to earnings growth through strategies like digitalization and supply chain optimization.
See More
Albertsons Reaches $774 Million Opioid Settlement Framework
- Settlement Framework: Albertsons Companies, Inc. has announced a $774 million settlement framework to resolve nearly all opioid-related claims from state, local, and tribal governments across the U.S., indicating a proactive approach to legal challenges.
- No Admission of Wrongdoing: The settlement does not imply any admission of wrongdoing or liability by Albertsons, highlighting the company's stance on legal accountability and aiming to protect its reputation while mitigating future legal risks.
- Stock Price Fluctuation: ACI closed at $16.34 on April 14, down $0.51 or 3.03%, but showed a modest rebound in after-hours trading, rising to $16.56, an increase of $0.22 or 1.35%, reflecting market reactions to the settlement news.
- Conditional Implementation: The agreement's execution is contingent upon certain conditions being met, demonstrating the company's cautious approach to navigating complex legal matters, which may also impact future financial planning and investor confidence.
See More
Albertsons Reaches $774M Opioid Settlement Amid Mixed Q4 Results
- Settlement Agreement: Albertsons has reached a $774 million opioid settlement with state, local, and tribal governments, which, while not admitting any wrongdoing, significantly aids in resolving most related litigation, thereby reducing future legal risks.
- Mixed Financial Results: Despite a 7.7% year-over-year sales increase to $20.25 billion, driven by a 16% rise in digital sales and a 0.7% increase in pharmacy transactions, the results fell short of expectations by $200 million, putting the company under greater market pressure.
- Slight Profit Growth: The company reported an adjusted profit of $0.48 per share, up 2 cents from last year and beating expectations by 4 cents, indicating resilience in profitability amidst adverse conditions, although it does not mask the overall weakness in financial performance.
- Cautious Future Outlook: Albertsons anticipates flat to 1% growth in identical sales for FY26, with full-year profit projections between $2.22 and $2.32 per share, closely aligning with consensus estimates, yet reflecting a cautious stance on future growth.
See More
Albertsons Q4 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: Albertsons reported a Q4 non-GAAP EPS of $0.48, exceeding expectations by $0.04, indicating resilience in profitability despite facing multiple challenges.
- Revenue Miss: Total revenue reached $20.25 billion, a 7.7% year-over-year increase, yet fell short of expectations by $200 million, reflecting the impact of store closures on overall performance.
- Strong Digital Sales: The company experienced a 16% increase in digital sales during Q4, showcasing success in its digital transformation, although overall sales were pressured by pricing headwinds in pharmacy sales.
- Cautious Outlook: For fiscal 2026, Albertsons anticipates identical sales growth between 0.0% and 1.0%, with adjusted EBITDA projected between $3.85 billion and $3.925 billion, indicating uncertainty in future market conditions.
See More
Albertsons Companies Announces Quarterly Dividend Increase
- Dividend Increase: Albertsons Companies has declared a quarterly dividend increase from $0.15 to $0.17 per share, representing a 13.3% rise, which indicates ongoing improvements in profitability and cash flow, thereby boosting investor confidence.
- Stable Yield: The forward yield of 4.04% not only attracts income-seeking investors but also enhances the stock's market appeal, potentially stabilizing its price amidst market fluctuations.
- Payment Schedule: The dividend will be payable on May 8, with a record date of April 24 and an ex-dividend date also on April 24, ensuring shareholders receive their returns promptly, which further solidifies shareholder loyalty.
- Market Reaction: With the dividend increase, market attention on Albertsons stock may rise, prompting investors to closely monitor the company's future financial performance and potential growth opportunities.
See More
Albertsons Reports $480.8 Million Net Loss in Q4
- Financial Decline: Albertsons reported a net loss of $480.8 million in Q4, translating to a loss of $0.94 per share, compared to a net income of $171.8 million or $0.29 per share last year, indicating increasing financial pressure on the company.
- Opioid Settlement Costs: The reported loss includes a $599.8 million charge, net of tax, or $1.18 per share, related to the Opioid Settlement Framework, highlighting a significant financial burden that could impact future profitability.
- Slight Decrease in Adjusted Net Income: The adjusted net income was $251.7 million, or $0.48 per share, down from $269.5 million, or $0.46 per share last year, reflecting ongoing challenges in maintaining profitability amidst rising costs.
- Cautious Future Outlook: For fiscal 2026, the company expects identical sales growth between 0.0% and 1.0%, with adjusted EBITDA projected between $3.850 billion and $3.925 billion, indicating a cautious approach due to market uncertainties.
See More
Albertsons Companies Q4 Fiscal 2025 Earnings Call Insights
- Sales Growth: Albertsons reported a 0.7% increase in identical sales for Q4 fiscal 2025, despite facing headwinds in its pharmacy business, indicating resilience in a competitive market.
- Profitability Metrics: The adjusted EBITDA reached $903 million, exceeding expectations, reflecting positive outcomes in cost control and operational efficiency, which helps bolster investor confidence.
- Shareholder Return Strategy: The company returned over $1.8 billion to shareholders in fiscal 2025, including $322 million in dividends and nearly $1.5 billion in share repurchases, demonstrating a strong commitment to capital management and shareholder value.
- Future Outlook: Management guided identical sales growth for fiscal 2026 to be between 0% and 2.5%, facing ongoing pharmacy sales pressures, but aims for a transition to earnings growth through strategies like digitalization and supply chain optimization.
See More
Albertsons Reaches $774 Million Opioid Settlement Framework
- Settlement Framework: Albertsons Companies, Inc. has announced a $774 million settlement framework to resolve nearly all opioid-related claims from state, local, and tribal governments across the U.S., indicating a proactive approach to legal challenges.
- No Admission of Wrongdoing: The settlement does not imply any admission of wrongdoing or liability by Albertsons, highlighting the company's stance on legal accountability and aiming to protect its reputation while mitigating future legal risks.
- Stock Price Fluctuation: ACI closed at $16.34 on April 14, down $0.51 or 3.03%, but showed a modest rebound in after-hours trading, rising to $16.56, an increase of $0.22 or 1.35%, reflecting market reactions to the settlement news.
- Conditional Implementation: The agreement's execution is contingent upon certain conditions being met, demonstrating the company's cautious approach to navigating complex legal matters, which may also impact future financial planning and investor confidence.
See More
Albertsons Reaches $774M Opioid Settlement Amid Mixed Q4 Results
- Settlement Agreement: Albertsons has reached a $774 million opioid settlement with state, local, and tribal governments, which, while not admitting any wrongdoing, significantly aids in resolving most related litigation, thereby reducing future legal risks.
- Mixed Financial Results: Despite a 7.7% year-over-year sales increase to $20.25 billion, driven by a 16% rise in digital sales and a 0.7% increase in pharmacy transactions, the results fell short of expectations by $200 million, putting the company under greater market pressure.
- Slight Profit Growth: The company reported an adjusted profit of $0.48 per share, up 2 cents from last year and beating expectations by 4 cents, indicating resilience in profitability amidst adverse conditions, although it does not mask the overall weakness in financial performance.
- Cautious Future Outlook: Albertsons anticipates flat to 1% growth in identical sales for FY26, with full-year profit projections between $2.22 and $2.32 per share, closely aligning with consensus estimates, yet reflecting a cautious stance on future growth.
See More
Albertsons Q4 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: Albertsons reported a Q4 non-GAAP EPS of $0.48, exceeding expectations by $0.04, indicating resilience in profitability despite facing multiple challenges.
- Revenue Miss: Total revenue reached $20.25 billion, a 7.7% year-over-year increase, yet fell short of expectations by $200 million, reflecting the impact of store closures on overall performance.
- Strong Digital Sales: The company experienced a 16% increase in digital sales during Q4, showcasing success in its digital transformation, although overall sales were pressured by pricing headwinds in pharmacy sales.
- Cautious Outlook: For fiscal 2026, Albertsons anticipates identical sales growth between 0.0% and 1.0%, with adjusted EBITDA projected between $3.85 billion and $3.925 billion, indicating uncertainty in future market conditions.
See More
Albertsons Companies Announces Quarterly Dividend Increase
- Dividend Increase: Albertsons Companies has declared a quarterly dividend increase from $0.15 to $0.17 per share, representing a 13.3% rise, which indicates ongoing improvements in profitability and cash flow, thereby boosting investor confidence.
- Stable Yield: The forward yield of 4.04% not only attracts income-seeking investors but also enhances the stock's market appeal, potentially stabilizing its price amidst market fluctuations.
- Payment Schedule: The dividend will be payable on May 8, with a record date of April 24 and an ex-dividend date also on April 24, ensuring shareholders receive their returns promptly, which further solidifies shareholder loyalty.
- Market Reaction: With the dividend increase, market attention on Albertsons stock may rise, prompting investors to closely monitor the company's future financial performance and potential growth opportunities.
See More
Albertsons Reports $480.8 Million Net Loss in Q4
- Financial Decline: Albertsons reported a net loss of $480.8 million in Q4, translating to a loss of $0.94 per share, compared to a net income of $171.8 million or $0.29 per share last year, indicating increasing financial pressure on the company.
- Opioid Settlement Costs: The reported loss includes a $599.8 million charge, net of tax, or $1.18 per share, related to the Opioid Settlement Framework, highlighting a significant financial burden that could impact future profitability.
- Slight Decrease in Adjusted Net Income: The adjusted net income was $251.7 million, or $0.48 per share, down from $269.5 million, or $0.46 per share last year, reflecting ongoing challenges in maintaining profitability amidst rising costs.
- Cautious Future Outlook: For fiscal 2026, the company expects identical sales growth between 0.0% and 1.0%, with adjusted EBITDA projected between $3.850 billion and $3.925 billion, indicating a cautious approach due to market uncertainties.
See More
